Search

Charles River Laboratories International Inc

Ouvert

SecteurSoins de santé

203.05 -0.19

Résumé

Variation du prix de l'action

24h

Actuel

Min

199.96

Max

203.85

Chiffres clés

By Trading Economics

Revenu

2.9M

56M

Ventes

-27M

1B

P/E

Moyenne du Secteur

592.3

78.892

BPA

2.43

Marge bénéficiaire

5.529

Employés

18,700

EBITDA

-23M

198M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

-1.14% downside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.2B

10B

Ouverture précédente

203.24

Clôture précédente

203.05

Sentiment de l'Actualité

By Acuity

100%

0%

362 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Charles River Laboratories International Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 déc. 2025, 15:21 UTC

Résultats

Correction to Home Depot Outlook Headline on Dec. 9

23 déc. 2025, 23:54 UTC

Market Talk

Gold Climbs Above $4,500/oz for First Time Amid Rising Geopolitical Tensions -- Market Talk

23 déc. 2025, 23:40 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

23 déc. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 déc. 2025, 21:21 UTC

Acquisitions, Fusions, Rachats

St Barbara to Use Deposit Toward A$370 Million Subscription to Buy 50% of Simberi Unit

23 déc. 2025, 21:20 UTC

Acquisitions, Fusions, Rachats

St Barbara to Hold Deposit in Escrow

23 déc. 2025, 21:20 UTC

Acquisitions, Fusions, Rachats

St Barbara: Deposit Represents Progress on Lingbao's Strategic Investment in Simberi Mine

23 déc. 2025, 21:19 UTC

Acquisitions, Fusions, Rachats

St Barbara Receives A$32 Million Deposit From Lingbao Gold

23 déc. 2025, 21:13 UTC

Acquisitions, Fusions, Rachats

ServiceNow Bets on Cybersecurity to Boost Growth -- Analysis

23 déc. 2025, 20:16 UTC

Market Talk

Oil Futures Settle Higher on Geopolitical Tensions -- Market Talk

23 déc. 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Soars on Colder Weather Outlook -- Market Talk

23 déc. 2025, 19:13 UTC

Résultats
Acquisitions, Fusions, Rachats

Mergers and Acquisitions Soared This Year. 2026 Could Be Even Bigger. -- Barrons.com

23 déc. 2025, 18:58 UTC

Market Talk

Gold Has Another Record-Setting Day -- Market Talk

23 déc. 2025, 18:32 UTC

Market Talk

U.S. Oil Rig Count Rises By 3 to 409 -- Market Talk

23 déc. 2025, 17:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

23 déc. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 déc. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

23 déc. 2025, 17:09 UTC

Market Talk
Acquisitions, Fusions, Rachats

Armis Seen as Good Fit for ServiceNow in $7.8B Deal -- Market Talk

23 déc. 2025, 16:21 UTC

Market Talk

Monthly Canadian GDP Points to Flat Activity So Far for 4Q -- Market Talk

23 déc. 2025, 16:16 UTC

Market Talk

Recent 'Disorderly' Yen Falls Could Justify Intervention -- Market Talk

23 déc. 2025, 16:15 UTC

Market Talk

Precious Metals Pare Gains -- Market Talk

23 déc. 2025, 16:03 UTC

Acquisitions, Fusions, Rachats

Erste Group Bank: Closing Expected Around Mid-January

23 déc. 2025, 16:03 UTC

Acquisitions, Fusions, Rachats

Erste Group Bank Also Obtained Regulatory Approvals for 50% Stake in Santander Towarzystwo Funduszy Inwestycyjnych

23 déc. 2025, 16:02 UTC

Acquisitions, Fusions, Rachats

Erste Group Bank Obtained Regulatory Approvals by Polish Regulator KNF for Acquisition of Roughly 49% Controlling Stake in Santander Bank Polska

23 déc. 2025, 16:01 UTC

Acquisitions, Fusions, Rachats

Erste Group Bank Receives Green Light for Acquisition in Poland

23 déc. 2025, 15:42 UTC

Acquisitions, Fusions, Rachats

Telefonica: Agreement is For Sale of Telefonica Tech Business in Colombia, Mexico, Chile

23 déc. 2025, 15:42 UTC

Acquisitions, Fusions, Rachats

Telefonica Doesn't Set Out Financial Details of Divestment

23 déc. 2025, 15:41 UTC

Acquisitions, Fusions, Rachats

Telefonica: Deal Will Allow Focus on Core Markets

23 déc. 2025, 15:40 UTC

Acquisitions, Fusions, Rachats

Telefonica To Sell Telefonica Tech South American Business to Hiberus

23 déc. 2025, 15:19 UTC

Market Talk

Fixed-Income Traders Misread Underlying Strength of Canada Economy -- Market Talk

Comparaison

Variation de prix

Charles River Laboratories International Inc prévision

Objectif de Prix

By TipRanks

-1.14% baisse

Prévisions sur 12 Mois

Moyen 200.55 USD  -1.14%

Haut 225 USD

Bas 170 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

7

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

117.16 / 144.77Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

362 / 374Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat